Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUVAL vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Hypertension (mild to moderate),Off-label: management of agitated states or psychiatric conditions (historically)
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Metabolized in the liver via CYP450 enzymes, primarily CYP3A4, to active and inactive metabolites.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
85-90% bound to albumin and alpha-1-acid glycoprotein.
~10-20% bound to plasma proteins (primarily albumin).
0.6-1.0 L/kg; indicates extensive extravascular distribution.
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Oral: 60-70% due to first-pass metabolism.
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, dose reduction by 50% is recommended.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Use with caution; maximum 1.5 mg daily.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Safety and efficacy not established in pediatric patients under 18 years.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Start at 1 mg orally once daily; consider slower titration due to increased sensitivity to orthostatic hypotension.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
None
None
May cause mental depression, especially at high doses, and should be discontinued if signs of depression appear.,Use with caution in patients with a history of peptic ulcer disease as it increases gastric acid secretion.,May cause orthostatic hypotension, tachycardia, and electrolyte disturbances.,Abrupt discontinuation may lead to withdrawal symptoms such as agitation, anxiety, and hypertension.
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Hypersensitivity to rauwolfia serpentina or any component,Active peptic ulcer disease,Ulcerative colitis,History of mental depression, especially with suicidal tendencies,Electroconvulsive therapy (ECT) within 7 days
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) as rauwolfia may potentiate pressor effects. Limit salt intake to support blood pressure control. Grapefruit juice may increase drug levels; avoid concurrent consumption.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
First trimester: Increased risk of cardiovascular malformations. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and neonatal renal impairment.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Rauval is excreted in human milk; potential for serious adverse reactions in nursing infants. M/P ratio unknown. Breastfeeding is contraindicated.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
No established dose adjustments; use is contraindicated in pregnancy due to known teratogenicity and fetotoxicity.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
Rauval (rauwolfia alkaloids) is an antihypertensive that depletes catecholamines. Avoid in patients with history of depression or peptic ulcer disease. Onset is slow (weeks), so not for hypertensive emergencies. Monitor for orthostatic hypotension, especially at initiation. May cause nasal congestion and bradycardia. Discontinue at least 2 weeks before elective surgery to avoid anesthetic interactions.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Take exactly as prescribed; do not stop abruptly as it may cause rapid blood pressure increase.,Avoid driving or operating machinery until you know how this medication affects you, as it may cause dizziness or drowsiness.,Rise slowly from sitting or lying down to prevent falls due to low blood pressure.,Report any signs of depression, slow heartbeat, or unusual bruising/bleeding to your doctor.,Avoid alcohol, as it may worsen dizziness and drowsiness.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUVAL vs ALDOMET, answered by our medical review team.
RAUVAL is a Antihypertensive that works by Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUVAL and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUVAL is: 1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUVAL and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUVAL is classified as Category C. First trimester: Increased risk of cardiovascular malformations. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and neonatal renal impairme. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.